Retrospective Analysis of Advanced Hepatocellular Carcinoma in the Elderly Treated with Domestic PD-1 Inhibitors combined with Lenva-tinib
10.11969/j.issn.1673-548X.2024.02.030
- VernacularTitle:国产PD-1抑制剂联合仑伐替尼治疗老年晚期肝癌回顾性分析
- Author:
Dandan YU
1
;
Li WANG
;
Huifang YUAN
Author Information
1. 450000 郑州颐和医院肿瘤内科
- Keywords:
Hepatocellular carcinoma;
Elderly;
PD-1/PD-L1 inhibitors;
Lenvatinib
- From:
Journal of Medical Research
2024;53(2):156-159
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy and safety of domestic programmed death-1(PD-1)ingibitor combined with lenvatinib in the treatment of advanced hepatocellular carcinoma in the elderly.Methods The clinical data of 37 elderly patients(o-ver 60 years old)with advanced hepatocellular carcinoma,who received domestic PD-1 inhibitors combined with lenvatinib in Zhengzhou Yihe Hospital from September 2021 to July 2022 were collected.Modified Response Evaluation Criteria in Solid Tumors(mRECIST)was used to evaluate the efficacy of intrahepatic lesions,and Response Evaluation Criteria in Solid Tumors(RECIST)1.1 was used to evaluate the efficacy of extrahepatic metastatic lesions.Kaplan-Meier method was used to evaluate the survival curve.Results Among the 37 elderly patients with hepatocellular carcinoma,8 patients achieved partial response,15 patients achieved stabilization,and 14 patients a-chieved disease progression.The objective response rate and the disease control rate were 21.6％(8/37)and 62.2％(23/37),respec-tively,and the median progression-free survival time was 5.885months(95％CI:5.374-6.397 months).The overall incidence rate of treatment-related adverse events was 51.4％(19/37).The most common adverse events were fatigue 27.0％(10/37),rash 27.0％(10/37)and hypertension 21.6％(8/37).Conclusion Domestic PD-1 inhibitors combined with lenvatinib is an effective and safe therapy for elderly patients with advanced hepatocellular carcinoma.
